Evidence map›Paper›PMID 37840095›Full record

Trial reportNature medicine2023

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

Thomas A Wadden, Ariana M Chao, Sriram Machineni, Robert Kushner, Jamy Ard, Gitanjali Srivastava, Bruno Halpern, Shuyu Zhang, Jiaxun Chen, Mathijs C Bunck and 2 more

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 240 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
240citing papers in PubMed, 19 pooled it
67.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06811324 phase2recruitingstarted 2026, after this paper: background citation

The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults

Ran2026Enrolled20Registered outcomes3Posted comparisons0ConditionsCardiovascular Function, GLP - 1, Obesity Prevention, Sarcopenia in ElderlyArmsTirzepatide
PMID 34170647PMID 24764133PMID 30048806PMID 30427277PMID 36508493PMID 35977298PMID 39265590PMID 38937282PMID 38829659PMID 38271277PMID 34562568PMID 35949358other papers from this trial
Open the trial in the graph
NCT07099742 not yet recruitingstarted 2025, after this paper: background citation

A Study of Real-World Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) in Bangladesh

Ran2025Enrolled364Registered outcomes11Posted comparisons0ConditionsObesityArmsLife style modification, Tirzepatide
PMID 35658024PMID 36498958PMID 37152942other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

240 citing papers in PubMed, 19 syntheses or guidelines pooled it, 336 citations in OpenAlex.

  1. Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025 · on this map
    Pooled it
  11. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  12. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025
    Guideline
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

180 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Thomas A WaddenDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. wadden@pennmedicine.upenn.edu.ORCID 0000-0002-0438-4609
Ariana M ChaoJohns Hopkins School of Nursing, Baltimore, MD, USA.
Sriram MachineniDivision of Endocrinology and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Robert KushnerDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jamy ArdDepartment of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0002-1643-6795
Gitanjali SrivastavaDepartment of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Pediatrics, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
Bruno HalpernObesity Group, Department of Endocrinology, Universidade de São Paulo, São Paulo, Brazil.
Shuyu ZhangEli Lilly and Company, Indianapolis, IN, USA.
Jiaxun ChenEli Lilly and Company, Indianapolis, IN, USA.
Mathijs C BunckEli Lilly and Company, Indianapolis, IN, USA.
Nadia N AhmadEli Lilly and Company, Indianapolis, IN, USA.
Tammy ForresterEli Lilly and Company, Indianapolis, IN, USA.ORCID 0009-0000-4712-3225
Eli Lilly (United States) · USAlbert Einstein College of Medicine · USJohns Hopkins University · USNorthwestern University · USUniversidade de São Paulo · BRUniversity of Pennsylvania · USVanderbilt University · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle intervention are unknown. This double-blind, placebo-controlled trial randomized (1:1) adults with body mass index ≥30 or ≥27 kg/m

Indexed as

Diabetes Mellitus, Type 2OverweightAdultDouble-Blind MethodGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsLife StyleObesityTirzepatideWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsTirzepatide

Identifiers

PMID37840095
PMCPMC10667099
OpenAlexW4387653463

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.